Molecule to Market: Inside the outsourcing space

M2M Monitor Special - 2026

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with our host Raman Sehgal. Raman distils dozens of executive conversations across 2025 into three key insights you can take into 2026 for you and your organization.    Molecule to Market is also sponsored by Bora Pharmaceuticals [https://boracdmo.com/] and Charles River Laboratories [https://www.criver.com/], and supported by Lead Candidate [https://leadcandidate.com/]. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

The master building CEO leading Codis

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Nick Fortin, Chief Executive Officer at Codis [https://codis.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering: * Nick’s desire to scratch that entrepreneurial itch, while recognising he was missing a key tool in his toolbox, which led him to pursue a midlife MBA. * His turnaround role at Neopharma exposed him to major players in the pharma services space, ultimately paving the way to Particle Dynamics (now Codis [https://codis.com/]). * The major pillars Nick established when he joined Particle Dynamics as CEO, and the company’s transformational journey that led to further investment, a major international acquisition, and the creation of Codis [https://codis.com/]. * Key lessons on managing multiple investors around the board table — and the critical role of a Chairman. * Why the bioavailability challenge for many molecules in the pipeline supports continued growth in spray drying. Nicolas joined Particle Dynamics as President and CEO in 2018. He has almost 30 years of experience in the pharmaceutical industry across multiple leadership roles. Nicolas earned a Bachelor’s degree in Engineering and holds an MBA from McGill and HEC Universities. Molecule to Market is sponsored by Bora Pharma (boracdmo.com [http://boracdmo.com/]) and Charles River (criver.com [http://criver.com/]), and supported by Lead Candidate [https://www.leadcandidate.com/]. Please subscribe, share with your industry colleagues, and join us in celebrating and promoting the value of the global life sciences outsourcing space. We’d also appreciate a positive rating!

From R&D to CRO CEO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Fozia Saleem, Chief Executive Officer at Magnitude Biosciences [https://magnitudebiosciences.com/]. Your host, Raman Sehgal, speaks with Fozia about the pharmaceutical and biotechnology supply chain, including: * How her early roles shaped her focus on applying science and innovation in a practical way * The contrast between working in tobacco and vape R&D and traditional pharma research * How a post-COVID reckoning led her to a CEO role at a university spin-out * The commercial potential of worms, the WormGazer® technology platform, and why Magnitude Biosciences [https://magnitudebiosciences.com/] is far from a cookie-cutter CRO * Fundraising, tripling the team, doubling lab space, and navigating the life of a scrappy CRO * How the company is helping clients with novel therapies get better insights earlier and faster amid a tough market environment Dr. Fozia Saleem is the CEO of Magnitude Biosciences [https://magnitudebiosciences.com/], a leading contract research organisation serving the pharmaceutical, health, and nutrition sectors to better understand the effects of drugs and nutraceuticals on healthy ageing, longevity, and neurodegeneration. With more than 15 years of experience across the FMCG and pharmaceutical industries — including leadership roles at GSK, BAT, and Broughton — Fozia has led global product launches, driven high-growth commercial strategies, and delivered transformative organisational change. Beyond her role at Magnitude Biosciences [https://magnitudebiosciences.com/], Fozia is a passionate advocate for women’s leadership and inclusive innovation. She previously co-chaired The Lifted Project – Newcastle Board, supporting high-growth female founders, and was named on the We Are Power Future List 2024 in recognition of her business leadership.   Molecule to Market is sponsored by Bora Pharmaceuticals [https://boracdmo.com/] and Charles River Laboratories [https://www.criver.com/], and supported by Lead Candidate [https://www.leadcandidate.com/]. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

M&A Roundtable Q4 2025 – Reflections and Predictions

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with: * Andrew Gigax, Head of European Pharma Services M&A at William Blair [https://www.williamblair.com/] * Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting * Sabina Ouimet Storrs, Principal at GHO Capital Partners [https://ghocapital.com/] * Jason Foss, Head of Corporate Development at Bora Pharmaceuticals [https://boracdmo.com/] Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including: * How market stabilisation has been overtaken by the need for adaptation in times of uncertainty * Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency * The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments * Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services * Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far * The shifts and trends that could reshape pharma services in the years ahead Molecule to Market is sponsored by Bora Pharma [https://boracdmo.com/], Charles River [https://www.criver.com/] and Lead Candidate [https://www.leadcandidate.com/], and supported by Lead Candidate [https://www.leadcandidate.com/]. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!

From Pharma to CRO entrepreneur

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest [https://pathoquest.com/Pathoquest]. The conversation covers: * Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure * The tough decision to refocus PathoQuest [https://pathoquest.com/Pathoquest] from diagnostics into a pure play CRO and pharma services business * How a major strategic partnership transformed the company’s trajectory and why Jean sees partnerships as a competitive weapon * Riding the tailwind of the FDA’s move away from animal testing and offering something game-changing in the CMC and GMP space * The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest [https://pathoquest.com/Pathoquest] in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest [https://pathoquest.com/Pathoquest], Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.   Molecule to Market is sponsored by Bora Pharma [https://boracdmo.com/], Charles River [https://www.criver.com/], and Lead Candidate [https://www.leadcandidate.com/]. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!